4//SEC Filing
Radius Health, Inc. 4
Accession 0001140361-14-009081
CIK 0001428522operating
Filed
Feb 20, 7:00 PM ET
Accepted
Feb 21, 5:29 PM ET
Size
16.1 KB
Accession
0001140361-14-009081
Insider Transaction Report
Form 4
F2 Capital Ltd
10% Owner
Transactions
- Purchase
Series B-2 Convertible Preferred Stock
2014-02-14$61.42/sh+227,938$13,999,952→ 227,938 total(indirect: See footnote)From: 2014-02-14→ Common Stock (2,279,380 underlying) - Purchase
Series B-2 Convertible Preferred Stock
2014-02-14$61.42/sh+110,713$6,799,992→ 110,713 total(indirect: See footnote)From: 2014-02-14→ Common Stock (1,107,130 underlying) - Purchase
Common Stock Warrant
2014-02-14+569,845→ 569,845 total(indirect: See footnote)Exercise: $6.14From: 2014-02-14Exp: 2019-02-14→ Common Stock (569,845 underlying) - Purchase
Common Stock Warrant
2014-02-14+276,783→ 276,783 total(indirect: See footnote)Exercise: $6.14From: 2014-02-14Exp: 2019-02-14→ Common Stock (276,783 underlying)
Priestley Katherine
10% Owner
Transactions
- Purchase
Series B-2 Convertible Preferred Stock
2014-02-14$61.42/sh+227,938$13,999,952→ 227,938 total(indirect: See footnote)From: 2014-02-14→ Common Stock (2,279,380 underlying) - Purchase
Series B-2 Convertible Preferred Stock
2014-02-14$61.42/sh+110,713$6,799,992→ 110,713 total(indirect: See footnote)From: 2014-02-14→ Common Stock (1,107,130 underlying) - Purchase
Common Stock Warrant
2014-02-14+569,845→ 569,845 total(indirect: See footnote)Exercise: $6.14From: 2014-02-14Exp: 2019-02-14→ Common Stock (569,845 underlying) - Purchase
Common Stock Warrant
2014-02-14+276,783→ 276,783 total(indirect: See footnote)Exercise: $6.14From: 2014-02-14Exp: 2019-02-14→ Common Stock (276,783 underlying)
Footnotes (4)
- [F1]Each share of the Series B-2 Convertible Preferred Stock has no expiration date and is convertible at any time, in whole or in part, at the election of the holder at a conversion rate of 10 shares of Common Stock for every 1 share of Series B-2 Convertible Preferred Stock.
- [F2]Payment of an aggregate purchase price equal to the product of (i) $61.42 multiplied by (ii) the total number of reported shares of Series B-2 Convertible Preferred Stock, entitled the purchaser to receive the reported shares of Series B-2 Convertible Preferred Stock as well as the reported warrant exercisable for shares of Common Stock.
- [F3]The reported securities are owned directly by F2 Bioscience IV L.P. ("F2 IV"). Each of F2 Biosciences IV GP Ltd. ("F2 IV GP"), Katherine Priestley, Globeways Holdings Limited ("Globeways") and F2 Capital Limited ("F2 Capital") are indirect beneficial owners of the reported securities. F2 IV GP is the General Partner of F2 IV. Katherine Priestley and Globeways are members of F2 IV GP. F2 Capital is an investment adviser to F2 IV. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F4]The reported securities are owned directly by F2 Bio Ventures V L.P. ("F2 Bio"). Each of F2 Bio Ventures GP Ltd., Globeways and F2 Capital are indirect beneficial owners of the reported securities. F2 Bio Ventures GP Ltd. is the General Partner of F2 Bio. Globeways is the sole member of F2 Bio Ventures GP Ltd. F2 Capital is an investment adviser to F2 V. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Documents
Issuer
Radius Health, Inc.
CIK 0001428522
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001428522
Filing Metadata
- Form type
- 4
- Filed
- Feb 20, 7:00 PM ET
- Accepted
- Feb 21, 5:29 PM ET
- Size
- 16.1 KB